Sponsor: Alliance for Clinical Trials in Oncology
Sponsor Study ID: A051901
Study Title: Phase I trial of Methotrexate, Rituximab, Lenalidomode, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
CTO #: 103979
NCT Number: NCT04609046
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Brain and Nervous System
Study Objectives: Determine the maximum tolerated dose (MTD) of lenalidomide when given in combination with HD-MTX and rituximab, with or without nivolumab, as induction treatment of primary CNS lymphoma. Determine the proportion of patients who are able to stay on maintenance therapy with lenalidomide and/or nivolumab for 6 months after induction treatment of primary CNS lymphoma.